CMPS Latest Headlines

COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating

at www.tipranks.com (Mon, 16-Mar 12:15 AM)

Compass Pathways Signals Confidence with Stifel CNS Forum Appearance as COMP360 Gains Regulatory Momentum

Market Chameleon (Thu, 12-Mar 9:01 AM)

CMPS Raises $200 Million from Warrant Exercises—Extends Cash Runway Through 2028, Boosts Funding for COMP360 Trials

Market Chameleon (Thu, 26-Feb 7:45 AM)

Compass Pathways Secures $150 Million to Advance Late-Stage Trials—What’s the Strategic Impact?

Market Chameleon (Thu, 19-Feb 7:11 AM)

Compass Pathways Announces $150 Million Public Offering: What This Means for the Company's Next Steps

Market Chameleon (Wed, 18-Feb 10:34 AM)

Compass Pathways Sets Stage for Key Phase 3 Data Reveal Amid Surging Investor Interest

Market Chameleon (Tue, 17-Feb 9:55 AM)

Phase 3 COMP360 Trial Achieves Key Depression Endpoint—Rapid and Durable Efficacy for Treatment-Resistant Patients

Market Chameleon (Tue, 17-Feb 7:05 AM)

FDA Clears Path for Compass Pathways' Late-Stage PTSD Study—Key Milestones Signal Momentum in Mental Health Innovation

Market Chameleon (Wed, 7-Jan 8:40 AM)